NCT04890795View on ClinicalTrials.gov

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Small Cell Lung Cancer
Interventions
DRUG

AL8326 tablets

10mg/tablet;Oral administration, once daily.

Trial Locations (9)

200000

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

210000

RECRUITING

General Hospital of Eastern Theater Command, Nanjing

221000

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

233000

RECRUITING

The first affiliated hospital of bengbu medical college, Bengbu

266000

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

610000

RECRUITING

Sichuan Cancer Hospital, Chengdu

Sponsors
All Listed Sponsors
lead

Advenchen Laboratories Nanjing Ltd.

INDUSTRY